3 Lucrative Stocks with Unresolved Issues

Profitability Isn’t Everything

While generating profits is crucial for any business, it doesn’t automatically ensure future growth or resilience. Companies that become complacent with their profit margins can quickly fall behind as competition heats up—a sentiment echoed by Jeff Bezos: "Your margin is my opportunity."

Although strong earnings are important, they’re not the sole indicator of a company’s long-term potential. At StockStory, our mission is to help you spot businesses with true staying power. With that in mind, here are three profitable companies we recommend avoiding, along with some superior alternatives to consider.

Somnigroup (SGI)

Trailing 12-Month GAAP Operating Margin: 10.1%

Somnigroup (NYSE:SGI) was formed in 2012 through the merger of Tempur-Pedic and Sealy. The company is recognized for its innovative sleep solutions, including memory foam mattresses and related products.

Reasons We’re Cautious About SGI

• SGI’s annual revenue has grown by 15.3% over the past five years, which lags behind other consumer discretionary companies.
• The company’s free cash flow margin is expected to remain flat in the near future.
• Returns on capital have been declining from an already low base, highlighting ineffective capital allocation by management.

Currently, SGI shares are priced at $80.02, representing a forward P/E ratio of 25.

Integra LifeSciences (IART)

Trailing 12-Month GAAP Operating Margin: 9.7%

Founded in 1989, Integra LifeSciences (NASDAQ:IART) is a leader in regenerative medicine, producing medical devices for neurosurgery, wound care, and reconstructive surgery, including advanced tissue and surgical tools.

Why We’re Not Bullish on IART

• Organic revenue growth has fallen short of expectations over the past two years, suggesting the need for improvements in product offerings, pricing, or sales strategy.
• Over the last five years, free cash flow margin has dropped by 19 percentage points, reflecting increased spending to defend market share.
• The company’s net-debt-to-EBITDA ratio stands at 6×, indicating high leverage and a greater risk of shareholder dilution if performance falters.

Integra LifeSciences trades at $9.61 per share, with a forward P/E of 4.2.

Illumina (ILMN)

Trailing 12-Month GAAP Operating Margin: 18.6%

Illumina (NASDAQ:ILMN) has revolutionized genetic research by making human genome sequencing faster and more affordable. The company supplies advanced DNA sequencing and microarray technologies used by scientists and healthcare professionals to study genetic variation and function.

Concerns About ILMN

• Organic sales growth over the past two years suggests the company may need to pursue strategic changes or acquisitions to accelerate expansion.
• Earnings per share have increased by just 1.5% annually over the last five years, trailing revenue growth, partly due to shareholder dilution.
• Low returns on capital indicate ongoing challenges in effective capital deployment by management.

Illumina is currently valued at $124.81 per share, or 25 times forward earnings.

Our Preferred Stock Picks

Don’t Miss: This Week’s Top 6 Stocks — The current market environment is quickly distinguishing high-quality stocks from overpriced ones, with AI-driven shifts impacting entire sectors unexpectedly. In such a dynamic market, you need more than just a list of solid companies.

Our AI-powered system identified Palantir before its 1,662% surge, AppLovin ahead of its 753% rally, and Nvidia before its 1,178% climb. Each week, it highlights six new stocks that meet our rigorous standards.

Past picks from 2020 include well-known names like Nvidia (up 1,326% from June 2020 to June 2025) and lesser-known companies such as Exlservice, which delivered a 354% five-year return.